×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
KZIA – kazia therapeutics limited - american depositary shares (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
KZIA
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
12/11
08:08 am
kzia
Kazia Therapeutics to Present Data Highlighting Synergistic Activity Between Paxalisib and Immunotherapy in Immunotherapy-Resistant Triple Negative Breast Cancer Model at the San Antonio Breast Cancer Symposium [Yahoo! Finance]
Low
Report
Kazia Therapeutics to Present Data Highlighting Synergistic Activity Between Paxalisib and Immunotherapy in Immunotherapy-Resistant Triple Negative Breast Cancer Model at the San Antonio Breast Cancer Symposium [Yahoo! Finance]
12/11
08:00 am
kzia
Kazia Therapeutics to Present Data Highlighting Synergistic Activity Between Paxalisib and Immunotherapy in Immunotherapy-Resistant Triple Negative Breast Cancer Model at the San Antonio Breast Cancer Symposium
Low
Report
Kazia Therapeutics to Present Data Highlighting Synergistic Activity Between Paxalisib and Immunotherapy in Immunotherapy-Resistant Triple Negative Breast Cancer Model at the San Antonio Breast Cancer Symposium
11/4
07:30 am
kzia
Kazia Therapeutics Announces Granting of Type C Meeting with FDA to Discuss Potential Next Steps for Paxalisib in the Treatment of Newly Diagnosed Glioblastoma Multiforme
High
Report
Kazia Therapeutics Announces Granting of Type C Meeting with FDA to Discuss Potential Next Steps for Paxalisib in the Treatment of Newly Diagnosed Glioblastoma Multiforme
10/2
08:45 am
kzia
Kazia Therapeutics Announces Presentation of Promising Phase I Data Evaluating Concurrent Paxalisib and Radiation Therapy in Patients with Solid Tumor Brain Metastases or Leptomeningeal Metastases Harboring PI3K Pathway Mutations at the American Society f
Low
Report
Kazia Therapeutics Announces Presentation of Promising Phase I Data Evaluating Concurrent Paxalisib and Radiation Therapy in Patients with Solid Tumor Brain Metastases or Leptomeningeal Metastases Harboring PI3K Pathway Mutations at the American Society f
9/23
08:30 am
kzia
Kazia Therapeutics Announces Presentation of EVT801 Clinical Data at 15th Biennial Ovarian Cancer Research Symposium
Medium
Report
Kazia Therapeutics Announces Presentation of EVT801 Clinical Data at 15th Biennial Ovarian Cancer Research Symposium
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
12/11
09:05 am
kzia
Form 424B3 KAZIA THERAPEUTICS LTD
Low
Report
Form 424B3 KAZIA THERAPEUTICS LTD
12/11
09:02 am
kzia
Form 424B3 KAZIA THERAPEUTICS LTD
Low
Report
Form 424B3 KAZIA THERAPEUTICS LTD
12/11
08:59 am
kzia
Form 6-K KAZIA THERAPEUTICS LTD For: Dec 11
Low
Report
Form 6-K KAZIA THERAPEUTICS LTD For: Dec 11
12/3
04:39 pm
kzia
Form 424B3 KAZIA THERAPEUTICS LTD
Medium
Report
Form 424B3 KAZIA THERAPEUTICS LTD
12/3
04:34 pm
kzia
Form 424B3 KAZIA THERAPEUTICS LTD
Medium
Report
Form 424B3 KAZIA THERAPEUTICS LTD
12/3
06:04 am
kzia
Form EFFECT KAZIA THERAPEUTICS LTD
Low
Report
Form EFFECT KAZIA THERAPEUTICS LTD
12/3
06:03 am
kzia
Form EFFECT KAZIA THERAPEUTICS LTD
Low
Report
Form EFFECT KAZIA THERAPEUTICS LTD
11/27
04:31 pm
kzia
Form POS AM KAZIA THERAPEUTICS LTD
Medium
Report
Form POS AM KAZIA THERAPEUTICS LTD
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
5/8
New positive data from phase IIa trial in brain cancer patients
12.8%
4/29 Kazia Therapeutics Ltd (NASDAQ: KZIA) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. 8.0%
8/20 Kazia Therapeutics Ltd (NASDAQ: KZIA) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. 4.7%
2/10 Kazia Therapeutics Ltd (NASDAQ: KZIA) was upgraded by analysts at ValuEngine from a "sell" rating to a "hold" rating. 3.2%
6/23 Edison issues ADR outlook on Kazia Therapeutics (KZIA) 3.1%
2/4 Kazia Therapeutics Ltd (NASDAQ: KZIA) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. 2.9%
1/7 Kazia Therapeutics Ltd (NASDAQ: KZIA) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. 2.1%
12/26 Kazia Therapeutics Ltd (NASDAQ: KZIA) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. 1.6%
4/4 Kazia Therapeutics Ltd (NASDAQ: KZIA) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $3.00 price target on the stock. 1.5%
6/27 Kazia Therapeutics Ltd (NASDAQ: KZIA) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $3.00 price target on the stock. 1.4%
4/29 Kazia Therapeutics Ltd (NASDAQ: KZIA) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. 8.0%
8/20 Kazia Therapeutics Ltd (NASDAQ: KZIA) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. 4.7%
2/10 Kazia Therapeutics Ltd (NASDAQ: KZIA) was upgraded by analysts at ValuEngine from a "sell" rating to a "hold" rating. 3.2%
6/23 Edison issues ADR outlook on Kazia Therapeutics (KZIA) 3.1%
2/4 Kazia Therapeutics Ltd (NASDAQ: KZIA) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. 2.9%
1/7 Kazia Therapeutics Ltd (NASDAQ: KZIA) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. 2.1%
12/26 Kazia Therapeutics Ltd (NASDAQ: KZIA) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. 1.6%
4/4 Kazia Therapeutics Ltd (NASDAQ: KZIA) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $3.00 price target on the stock. 1.5%
6/27 Kazia Therapeutics Ltd (NASDAQ: KZIA) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $3.00 price target on the stock. 1.4%
TOP News Decliners
11/20
Kazia Therapeutics up 83% [Seeking Alpha]
-18.9%
11/19 Kazia Therapeutics Ltd (NASDAQ: KZIA) was downgraded by analysts at ValuEngine from a "hold" rating to a "sell" rating. -8.6%
5/8 Kazia calls for greater awareness of the deadliest gynecological cancer in the US -8.5%
7/17 Kazia calls for greater awareness of the deadliest brain cancer in the US -8.4%
4/8 Kazia Therapeutics up 18% premarket on positive paxalisib data [Seeking Alpha] -8.0%
11/25 Positive Interim Efficacy Data from GDC-0084 Phase II Study in Glioblastoma Released at SNO Conference -7.4%
12/2 Edison issues ADR outlook on Kazia Therapeutics (KZIA) -6.7%
12/14 Kazia Therapeutics Ltd (NASDAQ: KZIA) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. -6.0%
1/14 Kazia Therapeutics Ltd (NASDAQ: KZIA) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. -2.9%
1/24 Kazia Therapeutics Ltd (NASDAQ: KZIA) was upgraded by analysts at ValuEngine from a "sell" rating to a "hold" rating. -2.4%
11/19 Kazia Therapeutics Ltd (NASDAQ: KZIA) was downgraded by analysts at ValuEngine from a "hold" rating to a "sell" rating. -8.6%
5/8 Kazia calls for greater awareness of the deadliest gynecological cancer in the US -8.5%
7/17 Kazia calls for greater awareness of the deadliest brain cancer in the US -8.4%
4/8 Kazia Therapeutics up 18% premarket on positive paxalisib data [Seeking Alpha] -8.0%
11/25 Positive Interim Efficacy Data from GDC-0084 Phase II Study in Glioblastoma Released at SNO Conference -7.4%
12/2 Edison issues ADR outlook on Kazia Therapeutics (KZIA) -6.7%
12/14 Kazia Therapeutics Ltd (NASDAQ: KZIA) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. -6.0%
1/14 Kazia Therapeutics Ltd (NASDAQ: KZIA) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. -2.9%
1/24 Kazia Therapeutics Ltd (NASDAQ: KZIA) was upgraded by analysts at ValuEngine from a "sell" rating to a "hold" rating. -2.4%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: